SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19
Nina Kreuzberger, Caroline Hirsch, Khai Li Chai, Vanessa Piechotta, Sarah J Valk, Lise J Estcourt, Susanne Salomon, E. Tomlinson, Ina Monsef, Erica M. Wood, Cynthia So‐Osman, David J. Roberts, Zoe McQuilten, Nicole Skoetz
Abstract
Objectives This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess whether SARS‐CoV‐2‐neutralising mAbs are effective and safe for treating patients with COVID‐19 in comparison to an active comparator, placebo or no intervention, and to maintain the currency of the evidence, using a living systematic review approach. A secondary objective is to track newly developing SARS‐CoV‐2‐targeting mAbs from first tests in humans onwards.
Topics & Concepts
Coronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Medicine2019-20 coronavirus outbreakMonoclonal antibodyVirologyPlaceboPandemicIntensive care medicineImmunologyAntibodyInternal medicineAlternative medicineOutbreakPathologyInfectious disease (medical specialty)DiseaseSARS-CoV-2 and COVID-19 ResearchVirus-based gene therapy researchBiomedical and Engineering Education